Bacteriology Division, United States Army Medical Research Institute of Infectious Disease (USAMRIID), Fort Detrick, Frederick, MD 21702, USA.
Vaccine. 2010 Jan 22;28(4):934-9. doi: 10.1016/j.vaccine.2009.10.143. Epub 2009 Nov 17.
A recombinant fusion protein composed of Yersinia pestis fraction 1 capsule (F1) and virulence-associated V antigen (V) (F1-V) has been developed as the next-generation vaccine against plague. In this study, female Swiss Webster mice received a single intramuscular vaccination with one of eight doses of the F1-V vaccine and exposed 4 weeks later to either Y. pestis CO92 or C12 organisms by the subcutaneous or aerosol routes of infection. Quantitative anti-F1 and anti-V immunoglobulin G (IgG) ELISAs were used to examine the relationship between survival outcome and antibody titers to F1 and V. Results suggested that each 1log(10) increase in week 4 quantitative anti-F1 and anti-V IgG ELISA titers were associated with a 1.7-fold (p=0.0051) and 2.5-fold (p=0.0054) increase in odds of survival, respectively, against either bubonic or pneumonic plague and may serve as serological correlates of protection.
一种由鼠疫耶尔森菌 F1 荚膜（F1）和与毒力相关的 V 抗原（V）组成的重组融合蛋白已被开发为新一代鼠疫疫苗。在这项研究中，雌性瑞士 Webster 小鼠接受了单次肌肉内接种 F1-V 疫苗的八种剂量之一，四周后通过皮下或气溶胶途径感染鼠疫耶尔森菌 CO92 或 C12 生物体。定量抗 F1 和抗 V 免疫球蛋白 G（IgG）ELISA 用于研究生存结果与抗 F1 和 V 抗体滴度之间的关系。结果表明，第 4 周定量抗 F1 和抗 V IgG ELISA 滴度每增加 1log(10)，分别与对抗败血型或肺鼠疫的生存几率增加 1.7 倍（p=0.0051）和 2.5 倍（p=0.0054）相关，可能作为保护的血清学相关物。
